Highlights from Castle’s DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin cancer, DecisionDx-SCC, DecisionDx®-Melanoma and MyPath® Melanoma, through poster presentations at the annual Maui Derm Hawaii meeting, being held Jan. 20-24, 2025, in Maui, Hawaii.
The Company’s poster on DecisionDx-SCC, which was selected as a “Late Breakers” top five finalist for the best poster Akamai Award, shares new data from a study involving Castle’s largest cohort of patients with cutaneous squamous cell carcinoma (SCC) to date (n=1,408). This study demonstrates improved risk stratification of patients with SCC tumors located on the head or neck when the test’s results are combined with Brigham and Women’s Hospital (BWH) staging.
“Patients with SCC tumors of the head or neck may be at increased risk of metastasis and thus could be candidates for adjuvant treatments, such as radiation, to reduce this risk,” said Dr. Emily Ruiz, M.D., MPH, FAAD, board-certified dermatologist and Mohs micrographic surgeon at Brigham and Women’s Hospital in Boston, and Associate Professor of Dermatology at Harvard Medical School. “As demonstrated in the study, using the DecisionDx-SCC test alongside BWH staging improved the overall accuracy of metastatic risk predictions in patients with these higher-risk SCC tumors to further inform decisions that clinicians make with their patients regarding the appropriate treatment aligned to their risk of metastasis.”
Castle’s posters at Maui Derm Hawaii, detailed below, will be available for viewing electronically on the conference app. Additionally, as a “Late Breaker” Five finalist, Castle’s DecisionDx-SCC poster will also be highlighted in a special podium presentation on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time.
DecisionDx-SCC
- Title: Metastasis-free survival prediction with the 40-gene expression profile (40-GEP) test in patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) risk stratified according to the Brigham and Women’s Hospital (BWH) tumor staging criteria
- Lead author: Emily S. Ruiz, M.D., MPH, Brigham and Women’s Hospital and Harvard Medical School, Boston
- Key take-aways: Using the largest combined patient cohort to date, this study assessed the ability of the DecisionDx-SCC test to stratify patients with HNcSCC according to their risk of metastasis and the prognostic value added to BWH staging through use of the test’s results. The study data demonstrated that DecisionDx-SCC was a significant predictor of metastasis, with distinct three-year metastasis-free survival rates provided across its risk classes: Class 1 (92.3%), Class 2A (81.3%), and Class 2B (57.8%). Further, combining DecisionDx-SCC test results with BWH staging significantly improved the accuracy of metastatic risk prediction (ANOVA p-value